Ovarian Cancer | Specialty

FDA Grants Olaparib Priority Review for Frontline Maintenance in Ovarian Cancer

November 12th 2018

The FDA has granted a priority review designation to a supplemental new drug application for olaparib tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer

November 10th 2018

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Real-World Data With Niraparib Show Lower AEs Vs ENGOT-OV6/NOVA Trial in Ovarian Cancer

November 8th 2018

Real-world incidences of nausea, thrombocytopenia, and fatigue were markedly lower in patients with platinum-sensitive, recurrent ovarian cancer receiving a starting 200-mg daily dose of niraparib versus those enrolled on the phase III ENGOT-OV6/NOVA trial.

PFS Improved With Maintenance Rucaparib in Recurrent Ovarian Cancer Irrespective of Prior Chemo

November 7th 2018

In patients with platinum-sensitive recurrent ovarian cancer, the PARP inhibitor rucaparib as maintenance treatment improved progression-free survival versus placebo, despite the number of chemotherapy regimens.

The Importance of Genetic Testing Following a Diagnosis of Ovarian Cancer

November 2nd 2018

Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the importance of genetic testing following a diagnosis of ovarian cancer.

Dr. Karam on Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Ovarian Cancer

October 27th 2018

Amer Karam, MD, associate clinical professor, Gynecologic Oncology, Stanford Hospital, director, Robotic Surgery and Outreach, Division of Gynecologic Oncology, Stanford Medicine, discusses primary debulking surgery versus neoadjuvant chemotherapy in the treatment of patients with ovarian cancer.

Dr. Powell on Tumor Mutational Burden in Ovarian Cancer

October 23rd 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.

Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer

October 22nd 2018

The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

ESMO 2018: Dr. Verma Sheds Light on Breast Cancer Data

October 21st 2018

ESMO 2018: Dr. Ramalingam Shares Insight on Lung Cancer Studies

October 21st 2018

ESMO 2018: Dr. Abou-Alfa Discusses Updates in GI Cancer

October 21st 2018

ESMO 2018: Dr. Cohen Reflects on Practice-Changing Data in Head and Neck Cancer

October 21st 2018

ESMO 2018: Dr. George Highlights Key Abstracts in Kidney and Prostate Cancers

October 21st 2018

ESMO 2018: Dr. Moore Speaks to Exciting PARP Inhibitor Abstracts in Ovarian Cancer

October 21st 2018

OncLive News Network On Location: In Munich Monday, October 22

October 21st 2018

OncLive News Network On Location: In Munich Sunday, October 21

October 21st 2018

OncLive News Network On Location: In Munich Saturday, October 20

October 21st 2018

Niraparib Effective in Later Lines of Therapy for Relapsed Ovarian Cancer

October 21st 2018

The PARP inhibitor niraparib has shown durable clinical activity in later lines of therapy in patients with relapsed ovarian cancer who have BRCA mutations, according to a posthoc analysis of the phase II QUADRA study.

Dr. Campos on Next Steps With PARP Inhibitors in Ovarian Cancer

October 15th 2018

Susana M. Campos, MD, gynecologic oncologist, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses next steps with PARP inhibitors in ovarian cancer.